222 related articles for article (PubMed ID: 34659242)
1. A Review of Cyclophosphamide-Induced Transplantation Tolerance in Mice and Its Relationship With the HLA-Haploidentical Bone Marrow Transplantation/Post-Transplantation Cyclophosphamide Platform.
Mayumi H
Front Immunol; 2021; 12():744430. PubMed ID: 34659242
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
Nunes NS; Kanakry CG
Front Immunol; 2019; 10():2668. PubMed ID: 31849930
[TBL] [Abstract][Full Text] [Related]
3. Human leukocyte antigen-haploidentical stem cell transplantation using T-cell-replete bone marrow grafts.
Fuchs EJ
Curr Opin Hematol; 2012 Nov; 19(6):440-7. PubMed ID: 22954723
[TBL] [Abstract][Full Text] [Related]
4. An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD.
Petrus MJ; Williams JF; Eckhaus MA; Gress RE; Fowler DH
Biol Blood Marrow Transplant; 2000; 6(2A):182-9. PubMed ID: 10816026
[TBL] [Abstract][Full Text] [Related]
5. CD40 ligand-specific antibodies synergize with cyclophosphamide to promote long-term transplantation tolerance across MHC barriers but inhibit graft-vs-leukemia effects of transplanted cells.
Prigozhina TB; Gurevitch O; Elkin G; Morecki S; Yakovlev E; Slavin S
Exp Hematol; 2003 Jan; 31(1):81-8. PubMed ID: 12543110
[TBL] [Abstract][Full Text] [Related]
6. HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide.
Fuchs EJ
Bone Marrow Transplant; 2015 Jun; 50 Suppl 2(0 2):S31-6. PubMed ID: 26039204
[TBL] [Abstract][Full Text] [Related]
7. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
[TBL] [Abstract][Full Text] [Related]
8. Post-transplantation cyclophosphamide for chimerism-based tolerance.
McCurdy SR; Luznik L
Bone Marrow Transplant; 2019 Aug; 54(Suppl 2):769-774. PubMed ID: 31431698
[TBL] [Abstract][Full Text] [Related]
9. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
[TBL] [Abstract][Full Text] [Related]
10. The induction of skin xenograft tolerance in rat-to-mouse combination could be affected by DFR mediating cells and antibodies against rat bone marrow cells as well as NK cells in the cyclophosphamide-induced tolerance system.
Nishimura Y; Eto M; Maeda T; Hiromatsu K; Nomoto K; Kong YY; Nomoto K
Immunobiology; 1995 Aug; 193(5):420-38. PubMed ID: 8522358
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.
Yu X; Liu L; Xie Z; Dong C; Zhao L; Zhang J; Gu J; Zhu HH
Crit Rev Oncol Hematol; 2019 Jan; 133():120-128. PubMed ID: 30661648
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts.
Ebens CL; McGrath JA; Tamai K; Hovnanian A; Wagner JE; Riddle MJ; Keene DR; DeFor TE; Tryon R; Chen M; Woodley DT; Hook K; Tolar J
Br J Dermatol; 2019 Dec; 181(6):1238-1246. PubMed ID: 30843184
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of transient treatment with FK506 in the early phase on cyclophosphamide-induced bone marrow chimerism and transplant tolerance across MHC barriers.
Okayama J; Ko S; Kanehiro H; Kanokogi H; Nakajima Y
J Surg Res; 2006 Jun; 133(2):61-8. PubMed ID: 16376943
[TBL] [Abstract][Full Text] [Related]
14. The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.
Eto M; Mayumi H; Tomita Y; Yoshikai Y; Nishimura Y; Nomoto K
Eur J Immunol; 1990 Sep; 20(9):2005-13. PubMed ID: 2209702
[TBL] [Abstract][Full Text] [Related]
15. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.
Robinson TM; O'Donnell PV; Fuchs EJ; Luznik L
Semin Hematol; 2016 Apr; 53(2):90-7. PubMed ID: 27000732
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation.
Stokes J; Hoffman EA; Zeng Y; Larmonier N; Katsanis E
Br J Haematol; 2016 Jul; 174(1):102-16. PubMed ID: 27030315
[TBL] [Abstract][Full Text] [Related]
17. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation.
Zeidan AM; Forde PM; Symons H; Chen A; Smith BD; Pratz K; Carraway H; Gladstone DE; Fuchs EJ; Luznik L; Jones RJ; Bolaños-Meade J
Biol Blood Marrow Transplant; 2014 Mar; 20(3):314-8. PubMed ID: 24296490
[TBL] [Abstract][Full Text] [Related]
18. Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.
Mayumi H; Good RA
J Exp Med; 1989 Jan; 169(1):213-38. PubMed ID: 2642528
[TBL] [Abstract][Full Text] [Related]
19. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies.
Katsanis E; Sapp LN; Varner N; Koza S; Stea B; Zeng Y
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2034-2039. PubMed ID: 29908231
[TBL] [Abstract][Full Text] [Related]
20. Flt-3L Expansion of Recipient CD8α
Markey KA; Kuns RD; Browne DJ; Gartlan KH; Robb RJ; Martins JP; Henden AS; Minnie SA; Cheong M; Koyama M; Smyth MJ; Steptoe RJ; Belz GT; Brocker T; Degli-Esposti MA; Lane SW; Hill GR
Clin Cancer Res; 2018 Apr; 24(7):1604-1616. PubMed ID: 29367429
[No Abstract] [Full Text] [Related]
[Next] [New Search]
